CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞输注后重度过敏反应：病例报告
英文原题：Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report.
查看英文原题
Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
病例报告：一名患者接受替沙仑赛（tisagenlecleucel）治疗后发生过敏性反应并心搏骤停。美国食品药品监督管理局不良事件报告系统中也记录了多例相关病例。鉴于过敏性反应可能危及生命，作者建议将其列为该疗法的重要风险。
展开英文摘要原文
Anaphylactic reactions at the time of chimeric antigen receptor T (CAR-T) cell infusion are adverse events that have not been reported in pivotal clinical trials or in real-world series.
We report the case of patient with severe anaphylaxis with cardiac arrest after tisagenlecleucel injection for Diffuse Large B cell Lymphoma, who recovered after resuscitation and intensive care treatment; we also conducted a Food and Drug Administration Adverse Event Reporting System database analysis and found several cases of severe anaphlyaxis after CAR-T cell injection.
Although not reported in pivotal CAR-T cell studies, anaphylaxis can occur after CAR-T cell injection, highlighting the need to include anaphylaxis as a possible side effect in future studies.
论文信息
- 作者
- Morin S、Boroli F、Vandenberghe-Durr S、Allali D、Masouridi-Levrat S、Chalandon Y、Simonetta F
- 单位
- Department of Oncology Division of Hematology Geneva University Hospitals Geneva Switzerland.Switzerland
- 文献类型
- 病例报告
- 期刊
- EJHaem2024 Jun
- 原文标识
- PubMed 38895058 · DOI 10.1002/jha2.874
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →